About Paul Bisaro
Paul Bisaro is a director at Pleopharma.
Paul Bisaro reports to the SEC as a director or officer of 10 public companies, including Keenova Therapeutics plc, Myriad Genetics (MYGN) and Zoetis (ZTS).
Paul Bisaro first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Paul Bisaro in the role, so the role may have started earlier or lasted longer.
Pleopharma, Inc.
Director
2022 – 2026 · Phoenixville, PA
Develops a drug for adults experiencing cannabis withdrawal.
KP
Keenova Therapeutics plc
Director
2022 – 2026 · Public company
MI
Myriad Genetics Inc.
Director
2022 – 2026 · Public company (MYGN)
ZI
Zoetis Inc.
Director
2015 – 2026 · Public company (ZTS)
TI
TherapeuticsMD, Inc.
Director
2020 – 2022 · Public company (TXMD)
AI
Amneal Pharmaceuticals, Inc.
Executive Chairman
2018 – 2019 · Public company (AMRX)
IL
Impax Laboratories, LLC
President and CEO, director
2017 – 2018 · Public company (IPXL)
AP
Allergan plc
Exec Chairman
2013 – 2018 · Public company (AGN)
ZI
Zimmer Biomet Holdings, Inc.
Director
2013 – 2017 · Public company (ZBH)
AI
Actavis, Inc.
President & CEO, director
2007 – 2013 · Public company (ACT)
BI
Barr Pharmaceuticals Inc.
President & COO, director
2006 – 2007 · Public company (BRL)
Key Colleagues at Startups
The people Paul Bisaro works with at each company, as listed on that company's latest Form D.
Pleopharma, Inc. · Form D, Aug 10, 2026
KT
Kyle Tomlin
Director
GC
Ginger Constantine
Executive officer and director
SH
Sarah Hassan
Director
JC
Jay Constantine
Chief Medical Officer, Co-Founder and Director
MT
McInerney Timothy
Director
TP
Thomas Poche
Executive officer
DC
Daniel Cartwright
Chief Financial Officer
RF
Robert Finizio
Executive Director
TT
Tommy Thompson
Director
KM
Kyle Mowitz
Director
BS
Brij Sharma
Director